10th Annual Dr. Ed Waits Respiratory Care Conference June 22, 2022

Absolute Risk

and

in the COVID-19 Pandemic

updated 6/25/22

Absolute Risk Reduction

James R. Boogaerts, MD, PhD, FACC **UAB** Division of Cardiovascular Disease







What will be covered:

3 numbers to consider when evaluating results of a clinical trial: perception

2 ways of thinking about the ongoing COVID-19 pandemic: perception

1 million ... how to conceptualize that large number: perception





















corona

webpage on imagessays.com











In 1741, anatomists first named the arteries which supply heart muscle:

"coronary arteries"








The word "corona" is a Latin word meaning "crown", from the Greek χορώνη.

E

















The word "corona" is a Latin word meaning "crown", from the Greek χορώνη.

E





"corona" during total eclipse of the sun




S proteins, spike (orange)

RNA (red)

E protein (yellow)


Lipid membrane-



coronavirus









The first confirmed death was on **January 9, 2020**

> **COVID-19** pandemic declared on March 11, 2020

As of June 22, 2022, more than 6,320,000 deaths had been attributed to COVID-19





cardiocerebral



See:

cardiocerebral

webpage on imagessays.com





from Latin verb: patior, pati, passus sum:

"one who suffers"

"patient"

to suffer





3 numbers to consider when evaluating results of a clinical trial

1) adverse event rate in the untreated group: (CER)

2) adverse event rate in the treated group: (TER)

3) reduction in adverse event rate conferred by treatment (ARR)




Absolute Risk Reduction (%)

Absolute Risk Reduction (%): ARR [reduction in adverse events (%) related to treatment]







imagessay S

Absolute Risk Reduction

(%)



See:

absolute

webpage on magessays.com



Control Group Event Rate (%): CER [adverse event rate (%) in control group]

Absolute Risk Reduction = CER minus TER

Treatment Group Event Rate (%): TER [adverse event rate (%) in treatment group]





Relative Risk Reduction (%): RRR is the difference between CER and TER divided by CER

RRR = (CER - TER) + CER = ARR + CER

This results in: RRR (%) >>> ARR (%)





Table 1. 2 \times 2 contingency table for SARS-C

	Infection	No Infection	
Vaccine	a	b	a + b
Placebo	с	d	c + d

$$RR = \frac{a/(a+b)}{c/(c+d)}$$
(Risk Ratio)

RRR = 1 - RR

Number needed to vaccinate (NNV):

Citation: Brown, R.B. Outcome Reporting Bias in COVID-19 mRNA Vaccine Clinical Trials. Medicina 2021, 57, 199. https://doi.org/10.3390/ medicina57030199

CoV-2 infection in vaccine clinical t	trials.
---------------------------------------	---------


Absolute risk reduction (ARR):

$$\operatorname{ARR}(\%) = \frac{c}{(c+d)} - \frac{a}{(a+b)}$$

Relative risk reduction (RRR) or vaccine efficacy (VE):

RRR, VE (%) =
$$1 - RR$$

$$NNV = \frac{1}{ARR}$$





COMMUNICATING **RISKS AND BENEFITS:**

An Evidence-Based User's Guide

Baruch Fischhoff PhD, Noel T. Brewer PhD, & Julie S. Downs PhD, editors



Published by the Food and Drug Administration (FDA), US Department of Health and Human Services, August 2011.

Contributors to this compilation are past or current members or consultants of the FDA's Risk Communication Advisory Committee. For more information on the committee, see http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/ RiskCommunicationAdvisoryCommittee/default.htm

FDA Disclaimer: The findings and conclusions in this compilation are those of the individual authors and do not necessarily represent the views of the Food and Drug Administration

There is no copyright in U.S. government work (per 17 U.S.C. 105), and the work provided here is considered U.S. government work.

Communicating Risks and Benefits: An Evidence-Based User's Guide is available on FDA's Web site at http://www.fda.gov/ScienceResearch/SpecialTopics/RiskCommunication/ default.htn

August 2011



US Department of Health and Human Services Food and Drug Administration 10903 New Hampshire Ave, Silver Spring, MD 20993


Cover photo: Nancy M. Ostrove, Rock formation, Valley of Fire State Park, 2009 Cover design: Erica Munoz, 2013

Provide numeric likelihoods of risks and benefits. Describing risks solely with words, such as You have a low chance of experiencing a side effect is ineffective. It does not provide patients with the details needed to make an informed decision; it increases risk perceptions, and patients vary in their interpretations of what low and high risks are. Thus, it is imperative to provide patients with numerical estimates of the risks and benefits associated with treatment options.


Provide absolute risks, not just relative risks. Patients are unduly influenced when risk information is presented using a relative risk approach; this can result in suboptimal decisions. Thus, an absolute risk format should be used.

Keep denominators constant for comparisons. It is difficult for patients to compare across treatments when different denominators are used. A single denominator should be chosen for comparisons (e.g., 1 in 10,000, 337 in 10,000). It is easier for patients to understand whole numbers (e.g., 1 in 10,000) rather than fractions or decimals (.01 in 100); thus, if risks are very small, larger denominators will be necessary.

















<u>1, 2, 3 - for clarity and transparency</u> <u>of clinical trials reporting</u>:


Control Group Event Rate (%) Treatment Group Event Rate (%) Absolute Risk Reduction (%)





A SARS-CoV-2 virus particle wafting into a person's nose or mouth is about 100 nanometers in diameter—visible only with an electron microscope. It is a near sphere of protein (cross section shown) inside a fatty membrane that protects a twisting strand of RNA—a molecule that holds the virus's genetic code. Proteins called "S" form spikes that extend from the surface and grab onto a human cell, hundreds of times larger, so the particle, or virion, can slip inside; the crown, or corona, appearance gives the virus its name. Structural proteins—N, M and E—move inside the cell, where they help new virions form.











Infectious Disease

Transmissible





A thing of beauty is a joy forever: Its loveliness increases; it will never Pass into nothingness; but still will keep A bower quiet for us, and a sleep Full of sweet dreams, and health, and quiet breathing.

John Keats, physician >>> poet, died at age 25 - in 1821 of an infectious, transmissible disease (tuberculosis), as did his mother and two of his brothers.

Infectious Disease

Transmissible

Endymion - Keats



The Plague (French: La Peste) is a novel by Albert Camus.

Published in 1947, it tells the story from the point of view of a narrator of a plague sweeping the French Algerian city of Oran.


Infectious Disease


Fransmissible

The Plague ALBERT CAMUS Winner of the Nobel Prize in Literature

"Everybody knows that pestilences have a way of recurring in the world; yet somehow we find it hard to believe in ones that crash down on our heads from a blue sky.


There have been as many plagues as wars in history; yet always plagues and wars take people equally by surprise."





Faces of health care in COVID-19

HISTORY OF **PANDEMICS**



Courtesy of Visual Capitalist.https://www.visualcapitalist.com/history-of-pandemics-deadliest/

PAN-DEM-IC (of a disease) prevalent over a whole country or the world.

the impact of COVID-19 because the disease is new to medicine, and data is still coming in.

Johns Hopkins University estimates



Historian John Barry compares COVID-19 to the 1918 flu pandemic

October 6, 2020



People wait in line to get masks in San Francisco during the 1918 Spanish flu pandemic. John Barry '69 (MA), author of The Great Influenza, says that one of the greatest lessons from 1918 that can be applied to the COVID-19 pandemic is that "those in authority must retain the public's trust." (Photo by Wikimedia Commons)

#1 NEW YORK TIMES BESTSELLER E GREAT The Story of the Deadliest Pandemic in History

John Barry '69 (MA) says that the virulence of the 1918 flu made it a very different disease than COVID-19, but the lessons of that pandemic still resonate.

When the novel coronavirus went from epidemic to pandemic early this year, John Barry '69 (MA) found himself in rather familiar territory. Barry is the author of The Great Influenza: The Epic Story of the Deadliest Plague in History. When the book was first published, in 2004, the National Academy of Sciences named it the outstanding book of the year on science and medicine. In 2020, Barry's book has returned to bestseller status.

In The Great Influenza, he considers what became known as the Spanish flu—so called because the press in Spain, which stayed neutral in World War I, had not clamped down on coverage in the name of morale—from a broad range of angles: scientists' quest to understand a new pathogen, officials' efforts (or lack thereof) to contain the spread of infection, and communities' and families' horrifying experiences of a disease so contagious and lethal that it infected about a quarter of the US population and killed between 50 and 100 million people around the world, the equivalent of 220 to 440 million today.


Anchoring The Great Influenza is Barry's consideration of leadership, science, and society. Trust, he argues, is crucial, because without trust in information people have no reliable knowledge of what is happening. In 1918, when leaders gave wartime morale priority over public health communication, terror overran


About John Barry

John Barry studied in the graduate program in history at the University of Rochester. He went on to work as a football coach and then as a journalist in Washington, DC, covering economics and national politics. He's now adjunct faculty at Tulane University's School of Public Health and Tropical Medicine and the author of books including The Great Influenza: The Epic Story of the Deadliest Plague in History, The Rising Tide: The Great

Mississippi Flood of 1927 and How It Changed America, and Roger Williams and the Creation of the American Soul: Church, State, and the Birth of Liberty.

society, so much so that some flu victims starved to death because others were too frightened to bring them food.





Nature is not cruel, only pitilessly indifferent. This is one of the hardest lessons for humans to learn. We cannot admit that things might be neither good nor evil, neither cruel nor kind, but simply callous - indifferent to all suffering, lacking all purpose.





Transmissible










oue Disease

Transmissible

Avoid crowded places







"All this has been said before—but since nobody listened, it must be said again."

Infectious Disease

Transmissible





1magessa 25 V






COVID-19 vaccine distribution began January 2021

See:



On imagessays.com








Figure 3 | Considerations for effectiveness of a directly injected mRNA vaccine. For an injected mRNA vaccine, major considerations for effectiveness include the following: the level of antigen expression in professional antigen-presenting cells (APCs), which is influenced by the efficiency of the carrier, by the presence of pathogenassociated molecular patterns (PAMPs) in the form of double-stranded RNA (dsRNA) or unmodified nucleosides and by the level of optimization of the RNA sequence (codon usage, G:C content, 5' and 3' untranslated regions (UTRs) and so on); dendritic cell (DC) maturation and migration to secondary lymphoid tissue, which is increased by PAMPs; and the ability of the vaccine to activate robust T follicular helper (TFH) cell and germinal centre (GC) B cell responses — an area that remains poorly understood. An intradermal injection is shown as an example. EC, extracellular.

MORE VIDEOS

Covid-19 Vaccine FAQ 1



Share

COVID-19 VACCINE FREQUENTLY ASKED QUESTIONS Cahaba lical Care

link to video

See link to video on *vaccines* webp










VACCINE TRACKER Learn more about vaccines +

Doses Administered 589,231,370



CORONAVIRUS **RESOURCE CENTER**



People Fully Vaccinated 221,506,997

% of Population Fully Vaccinated 67.23%





Citation: Brown, R.B. Outcome Reporting Bias in COVID-19 mRNA Vaccine Clinical Trials. Medicina 2021, 57, 199. https://doi.org/10.3390/ medicina57030199

PLACEBO

Control event rate (CER) 2/100 = 0.02 (2% risk)

VACCINE

1/100 = 0.01 (1% risk)


Figure 1. Example of a vaccine clinical trial for an infectious disease.

Experimental event rate (EER)



Absolute Risk Reduction (ARR) = Vaccine risk reduction CER - EER = ARR0.01 (1%) 0.02 0.01

Relative Risk Reduction (RRR) = Vaccine risk reduction relative to placebo risk ARR / CER = RRR 0.5 (50%) 0.02 0.01



Control event rate (CER) 2/100 = 0.02 (2% risk)

N \mathbb{N} \mathcal{D} MM ŝ RARRAR

Treatment Event Rate 1/100 = 0.01 (1% risk)

M 10

Absolute Risk Reduction = 1% Relative Risk Reduction = 50%






Figure 2. The chart shows critical appraisal results of mRNA COVID-19 vaccine efficacy.

COVID-19 Vaccine Efficacy <u>*in preventing infection</u>*

Absolute Risk Reduction

94.1%	Moderna Vaccine mRNA-1273 N = 30,420
.16% / 1.23% = 94.1%	
	Number Needed to Vaccinate = 88
1.1%	ARR: 1.23% - 0.07% = 1.16% (11/15,199 - 185/15,025)
	Infection No Infection mRNA-1273 11 15,199 15,210
	Placebo 185 15,025 15,210

Citation: Brown, R.B. Outcome Reporting Bias in COVID-19 mRNA Vaccine Clinical Trials. Medicina 2021 57, 199. https://doi.org/10.3390/ medicina57030199


From the article:

and 1.1% for t accines, respectively

in preventing infection

utcome reporting bias **COVID-19 vaccin** efficacy.





Pfizer

Absolute Risk Reduction

ARR RRR


Moderna

Citation: Brown, R.B. Outcome Reporting Bias in COVID-19 mRNA Vaccine Clinical Trials. Medicina 2021, 57, 199. https://doi.org/10.3390/ medicina57030199

From the article:

"Unreported <u>absolute</u> sk reduction measures of 0.7% and 1.1% for **Pfizer and Moderna** vaccines, respectively

essential to prevent outcome reporting bia in evaluation of **COVID-19** vaccine efficacy."







THE LANCET Microbe

COMMENT | VOLUME 2, ISSUE 7, E279-E280, JULY 01, 2021

COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room

Piero Olliaro 🖾 🛛 Els Torreele 🔹 Michel Vaillant Open Access Published: April 20, 2021

*** RR (relative risk) is the ratio of attack rates with and without a vaccine. ***




Figure: RRR and NNV with 95% CI ranked by attack rate in the unvaccinated (placebo) group for five COVID-19 vaccines

The lower the NNV and the higher the RRR, the better the vaccine efficacy. Details are in the appendix (p 3). RRR=relative risk reduction. NNV=numbers needed to vaccinate. NIH=US National Institutes of Health.

Vaccine efficacy is generally reported as a <u>Relative Risk Reduction</u> (RRR), which is: <u>1 - Relative Risk</u>

RRR should be seen against the background risk of being infected and becoming ill with COVID-19, which varies between populations and over time.

Although the RRR considers only participants who could benefit from the vaccine, the absolute risk reduction (ARR), which is the difference between attack rates with and without a vaccine, considers the whole population.

ARRs tend to be ignored because they give a much less *impressive effect size than* <u>RRRs</u>:

1.2% for the Moderna–NIH, 0.84% for the Pfizer-BioNTech vaccines. ***in preventing infection***





Perspective Outcome Reporting Bias in COVID-19 mRNA Vaccine Clinical Trials

Ronald B. Brown 回

School of Public Health and Health Systems, University of Waterloo, Waterloo, ON N2L3G1, Canada; r26brown@uwaterloo.ca

Abstract: Relative risk reduction and absolute risk reduction measures in the evaluation of clinical trial data are poorly understood by health professionals and the public. The absence of reported absolute risk reduction in COVID-19 vaccine clinical trials can lead to outcome reporting bias that affects the interpretation of vaccine efficacy. The present article uses clinical epidemiologic tools to critically appraise reports of efficacy in Pfzier/BioNTech and Moderna COVID-19 mRNA vaccine clinical trials. Based on data reported by the manufacturer for Pfzier/BioNTech vaccine BNT162b2,


Ironically, <u>the omission of absolute</u> risk reduction measures in data reviewed by the VRBPAC overlooks FDA guidelines for communicating evidence-based risks and benefits to the public [11]. The FDA's advice for information providers includes:

"Provide absolute risks, not just relative risks. Patients are unduly influenced when risk information is presented using a relative risk approach; this can result in suboptimal decisions. Thus, an absolute risk format should be used."

The New England Journal of Medicine also published clinical trial data on safety and efficacy for the BNT162b2 vaccine [12] and the mRNA-1273 vaccine [13], but with no mention of absolute risk reduction measures.

February 26, 2021






The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina

Dan-Yu Lin, Ph.D., Yu Gu, B.S., Bradford Wheeler, M.P.H., Hayley Young, M.P.H., Shannon Holloway, Ph.D., Shadia-Khan Sunny, M.D., Ph.D., M.P.H., Zack Moore, M.D., M.P.H., and Donglin Zeng, Ph.D.




March 10, 2022



The NEW ENGLAND JOURNAL of MEDICINE

Effectiveness of Covid-19 Vaccines over a 9-Month Period

OBSERVATIONAL STUDY USING SURVEILLANCE DATA FROM NORTH CAROLINA



D.-Y. Lin et al. 10.1056/NEJMoa2117128

Copyright © 2022 Massachusetts Medical Society



COVID-19 Cases, Hospitalizations, and Deaths by Vaccination Status



Disease Control and Health Statistics 1610 NE 150th Street, MS: K17-9 Shoreline, WA 98155

boosters.

Unvaccinated 12-34 year-olds in Washington are

- primary series.
- completed the primary series

Unvaccinated 35-64 year-olds are

- primary series.
- completed the primary series.

Unvaccinated 65+ year-olds are

- primary series.
- completed the primary series.
- primary series.

Washington State Department of Health

June 22, 2022

Washington State Department of Health

Public Health Outbreak Coordination, Information, and Surveillance

 On April 20, 2022, DOH updated COVID-19 vaccination language, changing the terms "initiating vaccination" and "fully vaccinated" to "initiated primary series" and "completed primary series." This change in language allows for better differentiation between original vaccine series and

1.9 times more likely to get COVID-19 compared with 12-34 year-olds who have completed the

2.9 times more likely to be hospitalized with COVID-19 compared with 12-34 year-olds who have

2.1 times more likely to get COVID-19 compared with 35 - 64 year-olds who have completed the

3.7 times more likely to be hospitalized with COVID-19 compared with 35 - 64 year-olds who have

3.1 times more likely to get COVID-19 compared with 65+ year-olds who have completed the

3.6 times more likely to be hospitalized with COVID-19 compared with 65+ year-olds who have

3.9 times more likely to die of COVID-19 compared with 65+ year-olds who have completed the





COVID-19 Cases, Hospitalizations, and **Deaths by Vaccination Status**

Washington State Department of Health

June 22, 2022




Age group	Age-specific rate per 100,000 in unvaccinated individuals	Age-specific rate per 100,000 in individuals who completed the primary series	Impact
12-34	1,813.5	941.9	1.9 times higher in unvaccinated
35-64	1,906.3	890.4	2.1 times higher in unvaccinated
65+	2,232.5	712.9	3.1 times higher in unvaccinated

Case rates are calculated using population data for the specified age group ٠

COVID-19 hospitalization rates per 100,000 population from May 11 to June 07, 2022

Age group	Age-specific rate per 100,000 in unvaccinated individuals	Age-specific rate per 100,000 in individuals who completed the primary series	Impact
12-34	26.6	9.2	2.9 times higher in unvaccinated
35-64	71.7	19.3	3.7 times higher in unvaccinated
65+	374.5	103.5	3.6 times higher in unvaccinated

Case rates are calculated using population data for the specified age group ٠








COVID-19 Cases, Hospitalizations, and **Deaths by Vaccination Status**

Washington State Department of Health

June 22, 2022







US Department of Health and Human Services/Centers for Disease Control and Prevention

MMWR / March 25, 2022 / Vol. 71 / No. 12

Effectiveness of mRNA Vaccination in <u>Preventing COVID-19–Associated</u> Invasive Mechanical Ventilation and Death — United States, March 2021–January 2022

TABLE 2. Effectiveness of COVID-19 mRNA vaccines against COVID-19-associated invasive mechanical ventilation or in-hospital death 21 hospitals, 18 states,*^{,†} March 2021–January 2022

Group/Characteristic	No. of vaccinated case- patients with IMV or death/ total no. of case-patients (%)	No. of vaccinated control- patients/ total no. of control-patients (%)	Vaccine effectiveness, % (95% CI)
All variant periods [§]	307/1,440 (21.3)	4,020/6,104 (65.9)	90 (88–91)
No. of mRNA vaccine doses received			
2	277/1,410 (19.6)	3,488/5,572 (62.6)	88 (86–90)
14–150 days after dose 2	92/1,225 (7.5)	2,039/4,123 (49.5)	92 (90–94)
>150 days after dose 2	185/1,318 (14.0)	1,449/3,533 (41.0)	84 (80-87)
3	30/1,163(2.6)	532/2,616(20.3)	94(91–96)
Age group, yrs			
18–64	115/931 (12.4)	1,807/3,326 (54.3)	91 (89–93)
≥65	192/509 (37.7)	2,213/2,778 (79.7)	88 (84–90)
Health status			
Immunocompromised	123/232 (53.0)	1,090/1,504 (72.5)	74 (64–81)
Immunocompetent	184/1,208 (15.2)	2,930/4,600 (63.7)	92 (91–94)
No. of chronic conditions among immunocompetent			
None	12/368 (3.3)	322/642 (50.2)	98 (97–99)
1	34/337 (10.1)	647/1,094 (59.1)	95 (92–96)
2	60/264 (22.7)	886/1,320 (67.1)	89 (85–93)
≥3	78/239 (32.6)	1,075/1,544 (69.6)	84 (78–89)
Variant period, [¶] no. of doses			
Pre-Delta, 2 doses	13/259 (5.0)	893/1,738 (51.4)	95 (90–97)
Delta, 2 or 3 doses	235/1,027 (22.9)	2,741/3,865 (70.9)	89 (87-91)
2 doses, median = 159 days after dose 2	218/1,010 (21.6)	2,402/3,526 (68.1)	88 (86-90)
3 doses, median = 35 days after dose 3	17/809 (2.1)	339/1,463 (23.2)	95 (91–97)
Omicron, 2 or 3 doses	59/154 (38.3)	386/501 (77.0)	86 (79–91)
2 doses, median = 256 days after dose 2	46/141 (32.6)	193/308 (62.7)	79 (66-87)
3 doses, median = 60 days after dose 3	13/108 (12.0)	193/308 (62.7)	94 (88–97)

Abbreviations: IMV = invasive mechanical ventilation; VE = vaccine effectiveness.

459

Summary

What is already known about this topic?


COVID-19 mRNA vaccines provide protection against COVID-19 hospitalization among adults. However, how well mRNA vaccines protect against the most severe outcomes of COVID-19–related illness, including use of invasive mechanical ventilation (IMV) or death, is uncertain.

What is added by this report?

Receiving 2 or 3 doses of an mRNA COVID-19 vaccine was associated with a 90% reduction in risk for COVID-19–associated IMV or death. Protection of 3 mRNA vaccine doses during the period of Omicron predominance was 94%.

What are the implications for public health practice?

COVID-19 mRNA vaccines are highly effective in preventing the most severe forms of COVID-19. CDC recommends that all persons eligible for vaccination get vaccinated and stay up to date with COVID-19 vaccination.









image ssays




webpage on **imagessays.com**

ECG

See:



AMI ECG, ANATOMY AND PATHOLOGY



RCA 'TYPE' LESIONS ±

INFERIOR MI

STE: II, III, aVF STD: aVL (reciprocal STE) RCA occlusion distal to RV 58% of MI

Seek and exclude INFERIOR AND RV MI STE: II, III, aVF and V1, V4R RCA occlusion proximal to RV 40% of Inferior MI Increased mortality risk

INFEROLATERAL MI

STE: II, III, AVF and I, aVL, VS, V6 ±V4R LAD and LOX occlusion in a L dominant system

INFEROPOSTERIOR MI STE: II, III, AVF and V7-9 STD: V1, V2 (reciprocal STE)

 $RS \ge 1: V1-2$ Tall T: V1-2 RCA and LCX occlusion

See: ECG Library - LITFL - ECG Library Basics - excellent interactive website



LCX LESIONS ± POSTERIOR MI STE:V7-9 STD: V1-2 (reciprocal STE) R5 2 1: V1-2 Tall T: V1-2 RCA and LCX occlusion

Seek and exclude POSTEROLATERAL MI STE: V7-9 and L aVL, V5-6 STD: V1, V2 LAD and LCX occlusion

INFEROPOSTERIOR MI STE: II, III, AVF and V7-9 STD: V1, V2 (reciprocal STE) R5 ≥ 1:V1-2 Tall T: V1-2 RCA and LCX occlusion

30 ALLE ROL 0 LAD LESIONS Combinations of the following SEPTAL MI STE:V1-2 LAD occlusion

> ANTERIOR MI STE:V3,V4 LAD occlusion


LATERAL MI STE: VS, V6, I, aVL LAD occlusion

+60


VISIBLE BODY* Nongo modge by Res Distance Spring on Mode 2 2015,252,253 248 © Argony Publishing, Inc., 2007-2010 Ad Rights Reserved 1) Graphics treated by Walkin Realy 30 sprintly provided at L. Howston Association on telever a well-indicating access

The 12-lead ECG records the electrical activity of the heart (depolarization / repolarization) **12 different viewpoints**

perspective


















posterior view












2 ways of thinking about the ongoing COVID-19 pandemic: perspective ... perception

Personal Health ... Me

Public Health ... Us



Number of coronavirus disease 2019 (COVID-19) deaths in the U.S. as of May 25, 2022, by age*





Risk for COVID-19 Infection, Hospitalization, and Death By Age Group

Updated June 2, 2022



Age group rate ratios compared to ages 18 to 29 years¹

Rate compared to 18-29 years old ¹	0-4 years old	5-17 years old	18-29 years old	30-39 years old	40-49 years old	50-64 years old	65-74 years old	75-84 years old	85+ years old
Cases ²	<1x	1x	Reference group	1x	1x	1x	1x	1x	1x
Hospitalization ³	1x	<1x	Reference group	2x	2x	Зx	5x	8x	10x
Death ⁴	<1x	<1x	Reference group	4x	10x	25x	65x	140x	330x

All rates are relative to the 18 to 29 years age group. This group was selected as the reference group because it has accounted for the largest cumulative number of COVID-19 cases compared to other age groups. Sample interpretation: Compared with ages 18 to 29 years, the rate of death is four times higher in ages 30 to 39 years, and 330 times higher in those who are ages 85 years and older. (In the table, a rate of 1x indicates no difference compared to the 18 to 29 years age group.)

Centers for Disease Control and Prevention CDC 24/7: Saving Lives, Protecting People™



Infectious Disease

Transmissible





Public Health ... Us

2 ways of thinking about the ongoing COVID-19 pandemic









As an example of an infected (and infectious) person who was not allowed to "do what she wanted to do", Mary Mallon was an asymptomatic carrier (in her gallbladder) of Salmonella typhi, which is infectious and causes typhoid fever. She chose and preferred to continue to work in her job as a cook (and to continue to spread typhoid fever to others who could become sick and die). She was not permitted to do so, however, because of the public health implications of this.



Mary Mallon, also called Typhoid Mary THE NEW YORK AMERICAN

The COVID-19 pandemic is a public health issue in addition to being a "personal choice", "freedom", "my decision" issue.


The health technology of the era did not have a completely effective solution: there were no antibiotics to fight the infection, and gallbladder removal was a dangerous, sometimes fatal operation. Some modern specialists claim that the typhoid bacteria can become integrated in macrophages and then reside in intestinal lymph nodes or the spleen.^{[50][51]}



Mary Mallon (September 23, 1869 -November 11, 1938), commonly known as Typhoid Mary, was an Irish-born American cook believed to have infected between 51 to 122 people with typhoid fever. The infections caused three confirmed deaths, with unconfirmed estimates of up to 50. She was the first person in the United States identified as an asymptomatic carrier of the pathogenic bacteria Salmonella typhi.^{[1][2]} She persisted in working as a cook and thereby exposed others to the disease. Because of that, she was twice forcibly quarantined by authorities, eventually for the final two decades of her life. Mallon died after a total of nearly 30 years in isolation.^{[3][4]} Her popular nickname has since gained currency as a term for persons who spread disease or other misfortune, not always aware that they are doing so.

In 1909, Mary unsuccessfully sued the health department. During her two-year period of confinement, she had 120/163 stool samples test positive. No one ever attempted to explain to Mary the significance of being a "carrier", instead they had offered to remove her gallbladder, something she had denied. She was unsuccessfully treated with Hexamethylenamin, laxatives, Urotropin, and brewer's yeast. In 1910, a new health commissioner vowed to free Mary and assist her with finding suitable employment as a domestic but not as a cook. Mary was released but never intended to abide by the agreement. She started working again in the cuisines of her unsuspecting employers, threatening public health once more [4].

As a cook of Sloane Maternity in Manhattan, she contaminated, in three months, at least 25 people, doctors, nurses and staff. Two of them died. She had managed to be hired as "Mary Brown" [8]. Since then she was stigmatized as "Typhoid Mary"



Jun 07, 2022 16:26 UTC (Eastern+5)

U.S. Population 332,749,749

Components of Population Change

One birth every 9 seconds One death every 13 seconds One international migrant (net) every 126 seconds

Net gain of one person every 23 seconds

ш

Select a Date





Learn More 🔁 | Download and Share 😂

World Population 7,900,634,46


TOP 10 MOST POPULOUS COUNTRIES (July 1, 2022)


1. China	1,410,539,758	6. Nigeria	225,082,083
2. India	1,389,637,446	7. Brazil	217,240,060
3. United States	332,838,183	8. Bangladesh	165,650,475
4. Indonesia	277,329,163	9. Russia	142,021,981
5. Pakistan	242,923,845	10. Mexico	129,150,971

Learn More 🔁 I Download and Share 😂









E ALABAMA AT BIRMINGHAM

JOHNS HOPKINS

UNIVERSITY & MEDICINE

CORONAVIRUS





Confirmed Cases 84,882,287

JOHNS HOPKINS

CORONAVIRUS RESOURCE CENTER

Past Week

Past Month

Deaths 1,008,857


... as of 6/7/22




Deaths Attributed to COVID-19 on Death Certificates



- upper bound threshold for excess deaths



Total Excess Deaths




022	2021	2020

In at least 90% of these deaths, COVID-19 was listed as the underlying cause of death. For the remaining deaths, COVID-19 was listed as a contributing cause of death.

This number reflects the total estimated number of excess deaths occurring since February 1, 2020.

Refer to "Number of Excess Deaths" dashboard listed under "Options."





Centers for Disease Control and Prevention CDC 24/7: Saving Lives, Protecting People™

National Center for Health Statistics

COVID-19 DEATHS



Data as of 6/2/2022

65-and-over ag

74.4% (748,084

Death by Age Gro

Data as of 6/2/2022 65-and-over ag

75.9% (119,085

Death by Age Gro

Data as of 6/2/2022

65-and-over ag

68.6% (317,453

Death by Age Gro

Data as of 6/2/2022

65-and-over ag

80.8% (311,54)

roup				
Total	2022	2021	2020	
34 deaths)	45-64 ag 21.3% (2 deat	14,550	4	Under 45 age group 4.2% (42,602 deaths)
oup				
Total ge group	2022 45-64 ag	2021 e group	2020	Under 45 age group
5 deaths)	20.3% (31,8		5) 3	3.7% (5,865 deaths)
coup				
Total	2022	2021	2020	Under / E age group
3 deaths)	45-64 ag 25.7% (1 deat	18,762	5	Under 45 age group .7% (26,554 deaths)
roup				
Total ge group	2022 45-64 ag	2021	2020	Under 45 age group
6 deaths)	16.6% (63,9		5) 2	2.6% (10,183 deaths)
			L	



The New York Cimes Inter the Anter the State "All the News That's Fit to Print" OL CLNIX No. 58,703 a sum the fee for the formation


SUNDAY, MAY 24, 2020

U.S. DEATHS NEAR 100,000, AN INCALCULABLE LOSS

<section-header><text><text><text><text><text> <text><text><text>

Memorial Day 2020 - 100,000 and counting ...

May 24, 2020




Concentrated in Project? 1,8,44, 1,111,111





<u>1 million ... how to conceptualize that large number</u>: perception



1,000,000 ... displayed as 10,000 dots / page <<<< *click here to view all 100 pages







	X 4	
		•••••
	den a	



30,000

















































































80,000









<u>1 million ... how to conceptualize that large number</u>

Million Dot Project

A central issue that confuses discussions of the human population on our planet is the inherent difficulty involved in intuitively grasping the size of large numbers. It is interesting that these numbers (million, billion, even trillion) have common usage, for example, in the press, usually when discussing cost, in dollars, of some governmental program. In the digital world, *mega-, giga-, and tera-* denote sizes of invisible processes that we take for granted. However, these words do not translate adequately or meaningfully into our perception of their true size, since they are so far outside any range with which we have direct experience. When we then incorporate these words (million, billion) into sentences describing groups of enormous size (when our own personal experience of a group is less than a hundred thousand or so), the ability to communicate important concepts on an intuitive level is exceedingly difficult.

Using a simple graphical demonstration, the reality of this conceptual difficulty may be illustrated. By creating a new *Word* document, and setting the format to a size 11 font, then entering dots (periods) as "......", one can fill a standard 8 $\frac{1}{2}$ " X 11" page with **10,000 dots**.

Copying this sheet 100X will yield 100 pages - each containing 10,000 dots - <u>1 million dots</u> total. Positioned <u>side by side</u>, these 100 sheets can be stretched out in a hallway to a length of <u>71 feet</u> (8 $\frac{1}{2}$ " X 100). Walking along this display, one may observe 1,000,000 dots. [Hint : *actually doing* this simple physical exercise – to *view* one million dots – is the point here.]

This gives a visual method to begin to obtain an intuitive concept of terms used when discussing the enormity of Earth's human population.

10,000	8.5 inches
100 thousand	7 feet
1 million	71 feet
19 million	0.25 miles
300 million	4 miles
1 billion	13 miles
7 billion	94 miles
10 billion	134 miles

Imagining these visual comparisons and then translating them into the relative size of human groups (filled megachurch @ 10,000, largest football stadium filled to capacity @ 100,000, large U.S. city @ 1 million, largest megalopolis areas @ 19 million, total U.S. population @ 300 million, populations of India or China @ 1 billion) gives a starting point to understand the <u>enormity</u> of Earth's human population (7 billion).

million dot project :

Open a *Word* document and use *size 11 font* to apply **10,000 periods (dots)** to a **8-1/2" x 11**" page.

Print 100 copies to generate <u>100 pages</u> then place all 100 pages side-by-side in a hallway: <u>71 feet long</u>.


Walk along the pages and observe **1 million dots**.

1,000,000 ... displayed as 10,000 dots / page <<<< *click here to view all 100 pages

*millior

webpage on imagessays.o






600,000 dead: With normal life in reach, covid's late-stage victims lament what could have been

June 11, 2021

600,000 ... displayed as 10,000 dots / page <<<< *click here to view all 60 pages

600,000




Bryant-Denny stadium: 101,821






Tiger stadium: 102,231



Sanford stadium: 92,746





US set to pass 800,000 COVID-19 deaths by late December

Deaths in 2021 greater than in 2020





Photo by: Centers for Disease Control and Prevention (CDC)

COVID-19

By: Tim Kephart

Posted at 11:41 AM, Nov 22, 2021 and last updated 10:41 AM, Nov 22, 2021

TAMPA, Fla. — The full picture of the COVID-19 pandemic will take decades to fully sort out, but we can see the grim number of deaths in real-time and it's about to cross over another threshold once thought too high to reach.








Covid's toll in the U.S. reaches a once unfathomable number: 1 million deaths

PUBLISHED WED, MAY 4 2022-4:37 PM EDT UPDATED WED, MAY 4 2022-6:20 PM EDT



WATCH LIVE




A white flag with a memorial written on it is one of the thousands of white flags representing Americans who have died of the coronavirus disease (COVID-19) placed over 20 acres of the National Mall in Washington, September 26, 2021. Joshua Roberts | Reuters

The United States on Wednesday surpassed 1 million Covid-19 deaths, according to data compiled by NBC News – a once unthinkable scale of loss even for the country with the world's highest recorded toll from the virus.


The number - equivalent to the population of San Jose, California, the 10th largest city in the U.S. – was reached at stunning speed: 27 months after the country confirmed its first case of the virus.











Neyland stadium: 102,455





Williams-Brice stadium: 80,250



Vaught-Herningway stadium: 64,038



Vanderbilt stadium: 40,350

1,000,000







The New York Times

Zhou Youguang, Who Made Writing Chinese as Simple as ABC, Dies at 111

🛱 Give this article 🖉 📮



Zhou Youguang in Beijing in 2011. Late in life, he became an outspoken critic of the Chinese government. Shiho Fukada for The New York Times

By Margalit Fox Jan. 14, 2017





When you encounter difficulties, you need to be optimistic.

The pessimists tend to die.

... quote from Zhou Yougang - father of Pinyin writing, who died at 111 (from 1/14/17 NYT obit)









<u>3 numbers to consider when evaluating results of a clinical trial:</u>

2 ways of thinking about the ongoing COVID-19 pandemic:

* personal health ... me * public health ... us

<u>1 million ... how to conceptualize that number</u>

What was covered:

* adverse event rate in untreated individuals (%) * adverse event rate in treated individuals (%) * absolute reduction in adverse event rate due to treatment (%)









